Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Comparing sequencing methods to detect chimeric sites for ex vivo cell and gene therapy and developing ISAL: A bioinformatics tool to monitor clonal dynamics of chimeric sites.

Andrew Kim, Jinhwa Jung, Young-Jun Lee et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15204

e15204 Background: Ex vivo cell and gene therapies such as autologous CAR-T cells recently have emerged as core modality f...

Sonesitatug vedotin (Sone-Ve) monotherapy in patients (pts) with claudin 18.2–positive (CLDN18.2+) advanced or metastatic gastric or gastroesophageal junction (GEJ) cancers: Data from CLARITY-PanTumor01.

Kohei Shitara, Kensei Yamaguchi, Hirokazu Shoji et al. Jun 01, 2026 pp. 4023-4023 10.1200/jco.2026.44.16_suppl.4023

4023 Background: Sone-Ve (AZD0901), an antibody-drug conjugate comprising an anti-CLDN18.2 antibody and monomethyl aurista...

Implementing ASCO’s PGA at an NCI-designated comprehensive cancer center.

Daniel Beau Stamos, Lauren Witek, Corey Obermiller et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13764

e13764 Background: Randomized controlled trials demonstrate that geriatric assessments (GA) improve outcomes for older adu...

Survival outcomes according to ramucirumab (RAM)-related hypertension (HTN) in patients (pts) with advanced HER2-negative gastric (G) or gastro-esophageal junction (GEJ) cancer: An exploratory analysis of the phase III ARMANI trial.

Roberta Fazio, Gabriele Tinè, Cecilia Villa et al. Jun 01, 2026 pp. 4051-4051 10.1200/jco.2026.44.16_suppl.4051

4051 Background: Retrospective studies suggest an association between treatment-related HTN and improved outcomes with ant...

Restrictive trial eligibility criteria as a barrier to clinical trial enrollment among veterans with aerodigestive cancers.

Sherwin Kelekar, Sadiq Rehmani, Charles John Nock et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13524

e13524 Background: Clinical trials are critical to advancing cancer care, yet enrollment remains low, with only 7.1% of ad...

Risk and survival outcomes of Hispanic patients with germ cell tumors at a multihospital academic center.

David Sheneman, Anush Ginosyan, Noah Suboc et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17007

e17007 Background: Testicular germ cell tumors (TGCTs) are the leading solid-organ malignancy of adolescent/young adult ma...

Anti-tumor activity of Man 9 x PS targeting immunotherapies in diffuse intrinsic pontine glioma (DIPG) and pancreatic cancers.

Shabnam Samimi, Jiadong Li, Kelly Mulraney et al. Jun 01, 2026 pp. 2530-2530 10.1200/jco.2026.44.16_suppl.2530

2530 Background: Aberrant cell-surface glycans and lipids are attractive immunotherapy targets due to their stable tumor e...

Projected trends in ischemic heart disease mortality among patients with multiple myeloma in the United States: A forecast analysis through 2035.

Daisha Rathod, Himanshu Khangwal, Neha Pillai Vinod et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e19544

e19544 Background: With progress in the treatment of multiple myeloma (MM), survival has improved significantly, and long-...

Implementing a clinical research coordinator–led care delivery model (CRC model) in an early-phase oncology program: A pilot to streamline workflow, improve collaboration, and enhance patient-centered trial conduct.

Christina Chukri, Ryan Kolonick, Dale Shepard et al. Jun 01, 2026 pp. 1585-1585 10.1200/jco.2026.44.16_suppl.1585

1585 Background: Early-phase oncology trials involve medically complex patients with narrow enrollment windows. Traditiona...

Palliative care utilization and disparities among adults with advanced cancer hospitalized for sepsis: A National Inpatient Sample analysis (2018–2021).

Amaani Lewis, Niketh Chopra, David LeRoy et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23194

e23194 Background: Sepsis is associated with high inpatient mortality, particularly among patients with advanced cancer. A...

A self-administered e-health dietary quality (DQ) assessment in patients (pts) at increased hereditary risk of cancer (CA): Feasibility and preliminary findings.

Lindsay G. Goldblatt, Nathaniel B. Gertzman, Jinhong Cui et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22544

e22544 Background: Pts at increased hereditary CA risk frequently express interest in “eating healthier”. Many providers h...

Targeting PI3K-β to develop novel combinational therapies for melanoma.

Maegan Gabby, Zhi Sheng Jun 01, 2026 pp. 2620-2620 10.1200/jco.2026.44.16_suppl.2620

2620 Background: Melanoma is the deadliest skin cancer, and more than 100,000 people in the United States were diagnosed i...

The impact of the COVID-19 pandemic on breast cancer stage at time of diagnosis at a major health system in New Jersey.

Maureen Younan, John Rutledge, Leah Shoshannah Gendler et al. Jun 01, 2026 pp. 11142-11142 10.1200/jco.2026.44.16_suppl.11142

11142 Background: The COVID-19 pandemic led to strict social distancing protocols in all aspects of daily life creating ba...

Antihistamine use and immune checkpoint inhibitor efficacy: An institutional analysis.

Jason Engel, John Clark Henegan Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24170

e24170 Background: Immune checkpoint inhibitor use has changed the treatment landscape for numerous solid tumor types. Pri...

Volumetric analysis of central nervous system hemangioblastomas during belzutifan treatment holiday in von Hippel–Lindau (VHL) disease patients.

Julien Rousseau, Maria Lampou, Timothy Richard West et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e22659

e22659 Background: Belzutifan produces durable volumetric responses in von Hippel–Lindau (VHL)–associated central nervous...

Microbiome associations with chemotherapy-induced nausea and vomiting: A metagenomic shotgun sequencing study.

Aasha I. Hoogland, Martine Extermann, Jin Xu et al. Jun 01, 2026 pp. 12110-12110 10.1200/jco.2026.44.16_suppl.12110

12110 Background: Chemotherapy-induced nausea and vomiting (CINV) is common, with four out of every ten patients reporting...

Comparison of different metrics for estimating kidney radiation exposure during treatment for childhood cancer: A report from the St. Jude Lifetime Cohort Study.

Daniel M. Green, Lu Xie, Matthew J. Krasin et al. Jun 01, 2026 pp. 10047-10047 10.1200/jco.2026.44.16_suppl.10047

10047 Background: Risk for impaired kidney function varies with radiation therapy (RT). We compared different methods for...

Real-world comparative safety and outcomes of ribociclib versus palbociclib in hormone receptor-positive, HER2-negative metastatic breast cancer: A propensity score–matched sensitivity analysis.

Noura Abbas, Gary Goldman, Layal Sharrouf Jun 01, 2026 pp. 1099-1099 10.1200/jco.2026.44.16_suppl.1099

1099 Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are widely used in hormone receptor-positive (HR+) / HER2...

Inspiring the next generation of medical oncologists: Passion, purpose, and preventing burnout.

Ruth Hutch, Alice Talbot, Caroline O'Leary et al. Jun 01, 2026 pp. 9015-9015 10.1200/jco.2026.44.16_suppl.9015

9015 Background: The National Cancer Registry of Ireland projects a doubling of cancer incidence by 2045, with an estimate...

Immunogenicity profiles in pediatric extra-cranial rhabdoid tumors: A framework for future risk stratification.

Omnia Al Qadi, Wael Zekri, Naglaa Elkinaai et al. Jun 01, 2026 pp. 10026-10026 10.1200/jco.2026.44.16_suppl.10026

10026 Background: Malignant rhabdoid tumors (MRTs) are highly aggressive pediatric cancers driven by SMARCB1 loss. Emergin...

Medicaid expansion and timely colorectal cancer treatment initiation among young adults in Virginia.

Paulette Omeaku, Arnethea Sutton, Bassam Dahman et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15679

e15679 Background: Colorectal cancer (CRC) remains a leading cause of cancer mortality in the United States, and incidence...

Gliofocus: A global, open-label, randomized phase 3 study comparing niraparib with temozolomide in newly diagnosed MGMT-unmethylated glioblastoma.

Nader Sanai, Shwetal Mehta, Artak Tovmasyan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps2102

TPS2102 Background: Glioblastoma (GBM) remains a fatal malignancy despite multimodality therapy. Approximately 60% of GBMs...

Racial disparities in utilization of bispecific T-cell engager therapy for relapsed/refractory multiple myeloma: A TriNetX study.

Emmanuel Ekpenyong, Chidiebube Ugwu, Maryam Mohsin et al. Jun 01, 2026 pp. 7545-7545 10.1200/jco.2026.44.16_suppl.7545

7545 Background: There have been remarkable advancements in the treatment of multiple myeloma over the past few decades. W...

Early changes in blood-based immune gene expression as a predictor of outcomes of <sup>177</sup> LuPSMA radioligand therapy in metastatic castration-resistant prostate cancer.

Mark S. Kidd, Kambiz Rahbar, Abdel B. Halim Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17066

e17066 Background: Metastatic castration-resistant prostate cancer (mCRPC) is characterized by an immunosuppressive tumor...

Survival trends and subsite variation in mucosal melanoma: A SEER database analysis.

Joseph Antony Elengickal, Bryan Michael Greenfield, Darren E. Mullins Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21606

e21606 Background: Mucosal melanomas are rare neoplasms, representing approximately 2% of all melanoma cases. They often p...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page